An international team of researchers has achieved a breakthrough in the production of doxorubicin, an important chemotherapy agent. This research identifies and resolves a molecular “bottleneck” that has limited the drug’s natural production for more than 50 years.
Doxorubicin is a chemotherapy drug that was first approved for medical use in the 1970s. It is the basis of treatment for a variety of cancers, including breast cancer, bladder cancer, lymphoma, and carcinoma, and more than 1 million patients are treated annually. However, bacteria naturally produce this important drug very inefficiently. As a result, the pharmaceutical industry has relied on expensive multi-step semi-synthetic processes.
We have uncovered several independent factors that limit doxorubicin production. By addressing these bottlenecks, we have leveraged rational strain engineering to pave the way for cost-effective manufacturing to meet growing global demand. ”
Dr. Keith Yamada, Principal Scientist, Researcher, University of Turku, Finland
Researchers develop a new type of bacteria that boosts drug production
This study was the result of an extensive international collaboration involving six laboratories: the University of Turku in Finland, three laboratories in the United States, and two laboratories in Leiden, the Netherlands.
Together, the research team identified three major constraints that prevent high-yield production of doxorubicin.
First, the research team identified specific natural “biological power supplies” (redox partners named Fdx4 and FdR3) that provide the flow of electrons needed to power drug-producing enzymes.
Second, they discovered that a protein called DnrV acts as a drug-binding “molecular sponge.” It sequesters (binds and holds) doxorubicin so that the drug does not shut down the enzyme’s own production machinery.
Finally, using X-ray crystallography, the team visualized the enzyme for the first time and revealed that the drug molecule was located in an unfavorable position within the enzyme, explaining the slow reaction rate.
By combining these findings, the researchers designed a new bacterial strain that produces 180% more doxorubicin than the current industrial standard.
To bring these discoveries to the real world, a spin-out company, Meta-Cells Oy, was established at the University of Turku last year. The company aims to commercialize these advanced technologies for the sustainable production of essential antibiotics and anti-cancer drugs. This transition to fully biosynthetic production promises a cleaner and more reliable supply of life-saving medicines.
sauce:
Reference magazines:
Koroleva, A. others. (2026). Metabolic engineering of doxorubicin biosynthesis by optimization of P450 redox partners and structural analysis of DoxA. nature communications. DOI: 10.1038/s41467-026-69194-6. https://www.nature.com/articles/s41467-026-69194-6
